DBV Technologies annonce le screening du premier participant de l’étude clinique de phase 2 THRIVE pour le patch VIASKIN® Peanut chez les nourrissons âgés de 6 à 12 mois allergiques à l’arachide

DBV Technologies announced the first participant screening in the THRIVE phase 2 clinical trial evaluating the efficacy and safety of VIASKIN® Peanut patch in infants aged 6-12 months with peanut allergies. The study aims to enable ad libitum peanut consumption through early intervention immunotherapy, building on positive results from earlier trials in older children.